Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 94153-53-4
Drug Levels and Effects
Summary of Use during Lactation
Information in this record refers to the use of fluoroestradiol F18 (18F-FES) as a diagnostic agent. No information is available on the clinical use of fluoroestradiol F18 during breastfeeding. The manufacturer recommends that mothers avoid breastfeeding for 4 hours after administration of fluoroestradiol F18. Nursing mothers should not work with radioactive substances used in PET scans in their workplace.[1]
Drug Levels
F18 is a positron emitter with a principal decay energy of 0.6335 MeV, annihilation photons of 0.511 MeV, and a physical half-life of 1.8 hours and 0.07% of an administered dose appears in breastmilk.[2] The maximum effective half-life is 0.89 hours.[3]
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Almén A, Mattsson S. Radiological protection of foetuses and breast-fed children of occupationally exposed women in nuclear medicine - Challenges for hospitals. Phys Med. 2017;43:172–7. [PubMed: 28882410]
- 2.
- Leide-Svegborn S, Ahlgren L, Johansson L, et al. Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations on breastfeeding interruption. Eur J Nucl Med Mol Imaging. 2016;43:808–21. [PubMed: 26732471]
- 3.
- ARSAC notes for guidance: Good clinical practice in nuclear medicine. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. 2020. https://www
.gov.uk/government /publications /arsac-notes-for-guidance. [PubMed: 10732169]
Substance Identification
Substance Name
Fluoroestradiol F18
CAS Registry Number
94153-53-4
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-(18)F-Fluoro-17β-Fluoroestradiol.[J Nucl Med. 2023]Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-(18)F-Fluoro-17β-Fluoroestradiol.Ulaner GA, Mankoff DA, Clark AS, Fowler AM, Linden HM, Peterson LM, Dehdashti F, Kurland BF, Mortimer J, Mouabbi J, et al. J Nucl Med. 2023 Mar; 64(3):351-354.
- Review Fludeoxyglucose F18.[Drugs and Lactation Database (...]Review Fludeoxyglucose F18.. Drugs and Lactation Database (LactMed®). 2006
- Review Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.[Oncologist. 2020]Review Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.Kurland BF, Wiggins JR, Coche A, Fontan C, Bouvet Y, Webner P, Divgi C, Linden HM. Oncologist. 2020 Oct; 25(10):835-844. Epub 2020 May 15.
- Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta-[18F]fluoro-5alpha-dihydrotestosterone (FDHT) as radiopharmaceuticals.[J Labelled Comp Radiopharm. 2014]Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta-[18F]fluoro-5alpha-dihydrotestosterone (FDHT) as radiopharmaceuticals.Zhou D, Lin M, Yasui N, Al-Qahtani MH, Dence CS, Schwarz S, Katzenellenbogen JA. J Labelled Comp Radiopharm. 2014 May 15; 57(5):371-7. Epub 2014 Feb 17.
- Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.[Clin Cancer Res. 1996]Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ. Clin Cancer Res. 1996 Jun; 2(6):933-9.
- Fluoroestradiol F18 - Drugs and Lactation Database (LactMed®)Fluoroestradiol F18 - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...